There is growing evidence that, apart from direct mechanisms of SGLT2 inhibitors, they have the molecular ability to inhibit acetylcholinesterase (AChE), thereby supporting synaptic function and neurotransmission, especially in patients with AD, as they have a reduced amount of acetylcholine neurotransmitters in the central nervous system [22]. Here, SLC5A2 is linked to Alzheimer disease.